Active	Status	Sponsor type	Region	Phase	Filter
1 Active 16 Inactive 17 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Angeliq (drospirenone/17ß-estradiol) / Bayer
NCT00623116: A Study to Characterize Epidemiology, Clinical and Genetic Features of Kallmann Syndrome in Finland	Enrolling by invitation	N/A	50	Europe	Short withdrawal of testosterone, gonadotropins or estrogenic compounds (see below)	Hospital for Children and Adolescents, Finland	Kallmann Syndrome	12/12	12/25